Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1083

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Hyperplasia
Osteoporosis

Interventions

DRUG: Bazedoxifene/Conjugated Estrogen
DRUG: Bazedoxifene/Conjugated Estrogen
DRUG: CE 0.45 mg/MPA 1.5mg
OTHER: Placebo

Sponsor

Pfizer